-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-04-08
FFTY:ARCA-Innovator IBD 50 Fund (USD)
ETF | Mid-Cap Growth | NYSE Arca
Last Closing
USD 23.76Change
-0.39 (-1.61)%Market Cap
USD 0.07BVolume
0.09M
N/A
Verdict
Values as of: 2025-04-08
ETF | Mid-Cap Growth | NYSE Arca
Last Closing
USD 23.76Change
-0.39 (-1.61)%Market Cap
USD 0.07BVolume
0.09MN/A
Verdict
The investment seeks long-term capital appreciation. Under normal circumstances, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in companies included in the IBD? 50 Index. The fund will generally hold all of the companies included in the IBD? 50 Index other than during periods when the fund is rebalanced due to changes in the constitution of the IBD? 50 Index. The fund, however, will not invest in the IBD? 50 Index companies in the same proportion as reflected in the index.
Company Website : www.innovatorfunds.com
Currency: USD
Country : USA
Inception Date: 08/04/2015
Primary Benchmark: IBD 50 Index USD
Primary Index: S&P 500 TR USD
Gross Expense Ratio: 1.13%
Management Expense Ratio: 0.80 %
N/A
N/A
N/A
N/A
Symbol | Name | Mer | Price(Change) | Market Cap |
---|---|---|---|---|
IWP | iShares Russell Mid-Cap Growth.. | 0.24 % |
-1.84 (-1.61%) |
USD 15.82B |
VOT | Vanguard Mid-Cap Growth Index .. | 0.07 % |
-2.83 (-1.20%) |
USD 14.48B |
IJK | iShares S&P Mid-Cap 400 Growth.. | 0.24 % |
-1.23 (-1.54%) |
USD 7.96B |
XMMO | Invesco S&P MidCap Momentum ET.. | 0.39 % |
-1.70 (-1.53%) |
USD 3.25B |
IVOG | Vanguard S&P Mid-Cap 400 Growt.. | 0.20 % |
-1.42 (-1.43%) |
USD 1.01B |
ETHO | Amplify ETF Trust | 0.45 % |
-0.94 (-1.83%) |
USD 0.18B |
CWS | AdvisorShares Focused Equity E.. | 0.68 % |
-0.68 (-1.08%) |
USD 0.17B |
BFOR | Barron's 400 ETF | 0.65 % |
-0.77 (-1.16%) |
USD 0.14B |
IPO | Renaissance IPO ETF | 0.60 % |
-0.60 (-1.66%) |
USD 0.13B |
PEXL | Pacer US Export Leaders ETF | 0.60 % |
-0.59 (-1.38%) |
USD 0.04B |
N/A
Market Performance vs. Industry/Classification (Mid-Cap Growth) | Market Performance vs. Exchange (NYSE Arca) | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -16.89% | 81% | B- | 30% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -16.89% | 81% | B- | 29% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -11.38% | 56% | F | 38% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -11.38% | 56% | F | 32% | F | ||
Trailing 5 Years | |||||||
Capital Gain | -14.69% | 11% | F | 25% | F | ||
Dividend Return | 3.07% | 17% | F | 6% | D- | ||
Total Return | -11.61% | 6% | D- | 14% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -2.92% | 11% | F | 21% | F | ||
Dividend Return | -2.23% | 11% | F | 14% | F | ||
Total Return | 0.69% | 61% | D- | 17% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 28.10% | 22% | F | 35% | F | ||
Risk Adjusted Return | -7.94% | 11% | F | 17% | F | ||
Market Capitalization | 0.07B | N/A | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.